<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6558">
  <stage>Registered</stage>
  <submitdate>16/06/2017</submitdate>
  <approvaldate>16/06/2017</approvaldate>
  <nctid>NCT03192280</nctid>
  <trial_identification>
    <studytitle>Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response</studytitle>
    <scientifictitle>Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>LHUB-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Skin Inflammation</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Leukotriene B4
Treatment: devices - FLIR One
Treatment: devices - SCIO
Treatment: devices - MS Band 2
Treatment: devices - AGE reader
Treatment: devices - HSI prototype (PARC) hyper-spectral camera
Treatment: devices - iPhone 7

Experimental: All study participants - Each subject will receive single topical induction application of Leukotriene B4 (LTB4) on the inner arm.
Images of the treated area will be captured using multiple medical devices.


Treatment: drugs: Leukotriene B4
Leukotriene B4 (LTB4)

Treatment: devices: FLIR One
Thermal imaging attachment to iPhone

Treatment: devices: SCIO
Handheld near-IR molecular spectroscopy device

Treatment: devices: MS Band 2
Wearable "watch-like" device with multiple sensors

Treatment: devices: AGE reader
Portable bench top device for in-clinic near UV assessment

Treatment: devices: HSI prototype (PARC) hyper-spectral camera
Portable bench top device for in-clinic multispectral imaging

Treatment: devices: iPhone 7
Smart phone

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time-point of change from baseline and comparator in electro-magnetic spectra as measured by HSI PARC - Spectra from 400 - 1000 nm in 5 nm increments</outcome>
      <timepoint>Day 1 to Day 3</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male aged &gt;25- &lt;40 years.

          -  Healthy, non-smoker.

          -  In the opinion of the investigator, the subject will be able to comply with the
             requirements of the protocol, including ability to present for all required visits.

          -  Subject is capable of understanding and signing an informed consent form.

          -  White origin (limit Skin Fitzpatrick I to III).</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Male aged &lt; 25 years or &gt;40 years.

          -  Female of any age.

          -  Tattoos on or within 5 cm of the area to be assessed.

          -  Scars on or with 5 cm of the area to be assessed.

          -  Current, active inflammatory skin disease, or past history of any inflammatory skin
             disease (other than acne) such as psoriasis, atopic dermatitis.

          -  Suffered from any significant allergies (i.e. food, environmental, contact).

          -  Subjects who are immunocompromised (i.e. HIV positive, Hepatitis C, transplant, etc.),
             based on clinical history.

          -  Subjects who currently have an activated immune system (e.g from current infection or
             recent vaccination).

          -  Subjects who have a history of chronic disease such as diabetes.

          -  Use of investigational therapy in the preceding month prior to screening visit.

          -  Use of G-CSF, GM-CSF, IL-2, IFNs, erythropoietin, systemic or inhaled steroids within
             one month of the screening visit.

          -  Use of oral analgesics/anti-inflammatories (e.g. paracetamol, ibuprofen, aspirin,
             codeine) or topical anti-inflammatories (e.g., ibuprofen) within 5 days of the
             screening visit.

          -  Concurrent disease or conditions that may present a risk to the subjects.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>19/06/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>12</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>6/07/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Investigational Site - Herston</hospital>
    <postcode>QLD 4006 - Herston</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>LEO Pharma</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial will test the feasibility of various imaging devices to detect local skin
      inflammation prior to clinical manifestation.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03192280</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul Griffin, MD</name>
      <address>Q-Pharm Pty Limited</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>